首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS
【24h】

Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS

机译:药草药物相互作用:LC-MS / MS对草药康交注射液组合施用的药代动力学研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Chinese herbal drugs are often combined with chemotherapy drugs for the treatment of cancers. However, the combination administrations often do not have scientifically sound bases established on full preclinical and clinical investigations. A commonly used anti-colon-cancer herb-drug pair, irinotecan (CPT-11) hydrochloride injection and Kang'ai (KA) injection was taken as an example to investigate the possible pharmacokinetic interactions between Chinese herbal drugs and chemotherapy injections to determine the potential adverse drug reactions (ADRs). Rats were randomly divided into three groups and received 20 mg/kg CPT-11 injection 15 min after administration of 4 mL/kg saline for the CPT-11 single administration group and 4 mL/kg KA injection for the separated co-administration group, respectively. In the pre-mixed co-administration group, rats received a mixture of 20 mg/kg CPT-11 injection and 4 mL/kg KA injection. Blood samples were collected at 10 pre-determined time points between 0 and 24 h. The tissue samples were collected at 5 and 8 min after the injections, respectively. A reliable LC-MS/MS method was established for the simultaneous determination of CPT-11 and its metabolites, SN-38, SN-38 G and APC in the rat plasma and tissue samples, after full confirmation of two injections chemical and stability compatibilities. Compared to the C-0 (5129 +/- 757 ng/mL) and AUC(0-t) (7858 +/- 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C-0 (4574 +/- 371 ng/mL) and AUC(0-t) (8779 +/- 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased Co (29,454 +/- 12,080 ng/mL) and AUC(0-t) (15,539 +/- 5165 ng h/mL) (p < 0.05). Since the exposures of CPT-11 in most tissues in the pre-mixed co-administration group were dramatically lower than the separated co-administration group, the increased CPT-11 plasma concentration may be produced by the delayed tissue distribution because of the encapsulation by the components contained in KA injection, such as polysaccharides. Similar differences were also found in its metabolite, SN-38 G. There are obvious herb-drug interactions between CPT-11 injection and KA injection after the pre-mixed co-administration. The resulting excessive CPT-11 in the plasma may lead to many serious ADRs. Therefore, the full evaluation of herb-drug interactions is necessary and inappropriate combinations should be avoided. (C) 2020 Elsevier B.V. All rights reserved.
机译:中草药常与化疗药物联合治疗癌症。然而,联合用药往往没有建立在完整的临床前和临床研究基础上的科学依据。以常用的抗结肠癌药物对盐酸伊立替康(CPT-11)注射液和康爱(KA)注射液为例,研究中药与化疗注射液之间可能存在的药代动力学相互作用,以确定潜在的不良反应(ADR)。将大鼠随机分为三组,分别在CPT-11单次给药组和单独联合给药组分别给予4ml/kg生理盐水15min后注射20mg/kg CPT-11和4ml/kg KA。在预混合共给药组中,大鼠接受20mg/kg CPT-11注射液和4ml/kg KA注射液的混合物。在0到24小时之间的10个预定时间点采集血样。分别在注射后5和8分钟采集组织样本。建立了一种可靠的LC-MS/MS方法,用于同时测定大鼠血浆和组织样品中的CPT-11及其代谢物SN-38、SN-38 G和APC,并充分确认了两次注射的化学相容性和稳定性。与CPT-11单次给药组中CPT-11的C-0(5129+/-757 ng/mL)和AUC(0-t)(7858+/-1307 ng h/mL)相比,单独给药后的C-0(4574+/-371 ng/mL)和AUC(0-t)(8779+/-601 ng h/mL)保持不变,但预混合给药导致co(29454+/-12080纳克/毫升)和AUC(0-t)(15539+/-5165纳克/小时/毫升)显著增加(p<0.05)。由于预混合共给药组中大多数组织中的CPT-11暴露量显著低于分离共给药组,因此,由于KA注射液中所含成分(如多糖)的包封,延迟组织分布可能会导致CPT-11血浆浓度增加。在其代谢产物SN-38 G中也发现了类似的差异。预混合给药后,CPT-11注射液和KA注射液之间存在明显的草药相互作用。由此产生的血浆中过量的CPT-11可能会导致许多严重的不良反应。因此,全面评估中草药与药物的相互作用是必要的,应避免不适当的组合。(C) 2020爱思唯尔B.V.版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号